SCHEMBL4298010

SCHEMBL4298010

CCCCC(COS(=O)(=O)c1ccc(C)cc1)COS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
MCHR1 Q99705 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PLA2G2C Q5R387 1/20 0.40
ALDH1A1 P00352 3/20 0.40
CYP2C9 P11712 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
LMNA P02545 1/20 0.38
ALB P02768 1/20 0.38
TSHR P16473 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
STAT3 P40763 2/20 0.38
CNR2 P34972 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23533337 0.95 MCHR1 (0.42) CA12CA2CA9MCHR1SMN1; SMN2
SCHEMBL2476440 0.94 ALDH1A1 (0.43) CA12CA2CA9MCHR1SMN1; SMN2
SCHEMBL29786761 0.93 ALDH1A1 (0.43) CA12CA2CA9MCHR1SMN1; SMN2
SCHEMBL20561114 0.93 MCHR1 (0.43) CA12CA2CA9MCHR1SMN1; SMN2
SCHEMBL26479527 0.91 MCHR1 (0.44) CA12CA2CA9MCHR1SMN1; SMN2
SCHEMBL13608639 0.91 MCHR1 (0.44) CA12CA2CA9MCHR1SMN1; SMN2
SCHEMBL3680210 0.91 MCHR1 (0.44) CA12CA2CA9MCHR1SMN1; SMN2
SCHEMBL1770004 0.91 MCHR1 (0.44) CA12CA2CA9MCHR1SMN1; SMN2
SCHEMBL4290352 0.90 CA12 (0.47) CA12CA2CA9SMN1; SMN2PLA2G2C
SCHEMBL27813828 0.90 PRSS1 (0.44) CA12CA2CA9MCHR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-1075448-A None JP disclosed
US-20090227616-A1 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION, A CORPORATION 2009-09-10 US disclosed
EP-1948185-A2 INHIBITORS OF AKT ACTIVITY SmithKline Beecham Corporation (US) 2008-07-30 EP disclosed
WO-2007058852-A2 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227616-A1 INHIBITORS OF AKT ACTIVITY PI4KB, PIK3CA, AKT2 CA12 4792/4885CA2 4115/4885CA9 3773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.